ClinicalTrials.govpublic full text
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
pancreatic cancer, advanced pancreatic cancer, metastatic pancreatic cancer, azd6244, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 894218
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.